Find your path to Rob
301 people in our graph can introduce you to Rob.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Stephane Castel to introduce you to Rob
You →Stephane · together at Variant Bio (2020–2026) →Rob
Ask Jamie Chen to introduce you to Rob
You →Jamie · together at PhRMA →Rob
Ask Sam Okafor to introduce you to Rob
You →Sam · 6 people · together at FDA →Rob
Sign up to find every way you can get introduced to Rob
- Your email: the people you already email who know Rob
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Rob
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
About
Rob Scott served as Chief Medical Officer at AbbVie and currently holds the position of Chief Medical Officer and Head of R&D at ABIONYX Pharma, where the company is developing a sepsis therapy. He brings nearly four decades of executive leadership experience across drug discovery, development, strategic lifecycle planning, and medical affairs at major pharmaceutical and biotech companies, and maintains board and advisory positions at multiple biotech, venture capital, and private equity firms.
Experience
- ABIONYX PharmaChief Medical Officer & Head of R&Dcurrent2024 — present
- Confo TherapeuticsBoard Membercurrent2020 — present
- Draupnir BioBoard Membercurrent2020 — presentCopenhagen, Capital Region of Denmark, Denmark
- Variant BioBoard Membercurrent2020 — present
- OncoSpherixBoard Membercurrent2021 — presentAtlanta, Georgia, United States
- Bioethics InternationalAdvisorcurrent2017 — present
- Redx PharmaBoard Member2022 — 2024Manchester Area, United Kingdom
- ArisGlobalBoard Member2020 — 2024
- Windtree Therapeutics, Inc.Board Member2021 — 2024
- Morningside BioPharma AdvisoryStrategic Advisor2020 — 2023
- AbbVieChief Medical Officer, Head of Development2016 — 2020Greater Chicago Area
- Chicago Council on Science and Technology (C2ST)Board Member2019 — 2020Greater Chicago Area
- PhRMAR&D Leadership Forum2016 — 2020Greater Chicago Area
- TransCelerate BioPharma Inc.Board Member2016 — 2020Greater Chicago Area
- Kanan Therapeutics, Inc.Chairman of the Board2016 — 2018Los Angeles Metropolitan Area
- AmgenVice President, Global Development TA Head, Head Development Design Center2010 — 2016Los Angeles Metropolitan Area
- FDACommittee Member2012 — 2015Washington DC-Baltimore Area
- Cerenis TherapeuticsChief Medical Officer2008 — 2010Greater Toulouse Metropolitan Area
- AtheroGenicsChief Medical Officer, Executive Vice President of Research & Development2002 — 2007Atlanta Metropolitan Area
- PfizerVice President Cardiovascular & Metabolic Group1992 — 2002New York City Metropolitan Area
- Johnson & JohnsonMedical Advisor1987 — 1989City of Johannesburg, Gauteng, South Africa
Skills & more
+12 more
FDACommercializationPharmacologyStrategyPharmaceuticsMedical DevicesBiopharmaceuticalsTherapeutic AreasR&DMedical AffairsLifesciencesCardiologyFrom Rob's professional profile.
Colleagues at Apollo Health Ventures
Frequently asked questions
- Who is Rob Scott?
- Rob Scott served as Chief Medical Officer at AbbVie and currently holds the position of Chief Medical Officer and Head of R&D at ABIONYX Pharma, where the company is developing a sepsis therapy. He brings nearly four decades of executive leadership experience across drug discovery, development, strategic lifecycle planning, and medical affairs at major pharmaceutical and biotech companies, and maintains board and advisory positions at multiple biotech, venture capital, and private equity firms.
- Where does Rob Scott work?
- Rob Scott is Advisor at Apollo Health Ventures.
- Where did Rob Scott go to school?
- Rob Scott studied at University of Cape Town (MbChB, Medicine); University of Cape Town (BSc, Microbiology and Biochemistry).
Same school
Also attended University of Cape Town302
+ 296 more
Shared employers
Also worked at Confo Therapeutics6
Also worked at Variant Bio3
Also worked at Windtree Therapeutics, Inc.4
Also worked at AbbVie66
+ 60 more













































